Paratek Pharmaceuticals Completes Combination with Radius Health
March 20, 2026
Paratek Pharmaceuticals completed its combination with Radius Health, adding Radius’s osteoporosis therapy TYMLOS (abaloparatide) to Paratek’s specialty pharmaceutical portfolio. The combined company is expected to generate nearly $1 billion in revenue in 2026 and expands the platform across multiple high-need therapeutic areas.
- Buyers
- Paratek Pharmaceuticals, Inc., B-FLEXION Life Sciences, Blackstone Credit & Insurance, Sixth Street, Oaktree Capital Management, L.P., Silver Point Capital, Pharmakon Advisors, LP
- Targets
- Radius Health, Inc.
- Platforms
- Paratek Pharmaceuticals, Inc.
- Industry
- Pharmaceuticals
- Location
- Pennsylvania, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.